Roxall Medizin   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Zamudio Spain (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2008
NCT01012531
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Roxall Medicina España S.A

Active Ingredients

Drugs in Phase 3 Trials (2)

house dust mite allergen (4 trials)

timothy grass pollen allergen extract (Grastek) (1 trial)

Drugs in Phase 2 Trials (1)

trifolium pratense (4 trials)

Drugs in Phase 1 Trials (2)

OLEA EUROPAEA (2 trials)

parietaria judaica pollen extract (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 1)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 5